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Purpose: To evaluate and compare outcome of stereotactic body radiation therapy (SBRT),
yttrium-90 radioembolization, radiofrequency ablation (RFA), or transarterial chemoembolization
(TACE) as bridge to liver transplant (LT) in patients with hepatocellular carcinoma.
Methods and materials: We retrospectively reviewed patients treated at our institution with
SBRT, TACE, RFA, or yttrium-90 as bridge to LT between 2006 and 2013. We analyzed
radiologic and pathologic response and rate of failure after bridge therapy. Toxicities were reported
using Common Terminology Criteria for Adverse Events, 4.0. Kaplan-Meier method was used to
calculate disease-free survival (DFS) and overall survival after LT.
Results: Sixty patients with a median age 57.5 years (range, 44-70) met inclusion criteria. Thirty-
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36 M. Mohamed et al Advances in Radiation Oncology: JanuaryeMarch 2016nonalcoholic steatohepatitis cirrhosis. Patients received a total of 79 bridge therapies: SBRT (nZ
24), TACE (n Z 37), RFA (n Z 9), and Y90 (n Z 9). Complete response (CR) was 25% for
TACE, 8.6% for SBRT, 22% for RFA, and 33% for Y90. Grade 3 or 4 acute toxicity occurred
following TACE (n Z 4) and RFA (n Z 2). Transplant occurred at a median of 7.4 months after
bridge therapy. Pathological response among 57 patients was 100% necrosis (n Z 23, 40%),
>50% necrosis (n Z 20, 35%), <50% necrosis (n Z 9, 16%), and no necrosis (n Z 5, 9%).
Pathologic complete response was as follows: SBRT (28.5%), TACE (41%), RFA (60%), Y90
(75%), and multiple modalities (33%). At a median follow-up of 35 months, 7 patients had
recurrence after LT. DFS was 85.8% and overall survival was 79% at 5 years.
Conclusion: All bridge therapies demonstrated good pathological response and DFS after LT.
SBRT and Y90 demonstrated signiﬁcantly less grade 3 acute toxicity. Choice of optimal mo-
dality depends on tumor size, pretreatment bilirubin level, Child-Pugh status, and patient
preference. Such a decision is best made at a multidisciplinary tumor board as is done at our
institution.
Copyright ª 2016 the Authors. Published by Elsevier Inc. on behalf of the American Society for
Radiation Oncology. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Hepatocellular carcinoma (HCC), the most common
primary malignancy of the liver, is the sixth most common
cancer worldwide and the third leading cause of cancer
mortality.1 In 2014, there were 33,190 new cases of liver
cancer and 23,000 resultant deaths in the United States.2
Liver transplantation (LT) offers the best results in terms
of overall survival (OS) and disease-free survival (DFS) for
selected patients with HCC.3 After the Milan criteria were
established (single nodule <5 cm or 3 nodules <3 cm),
promising results have been reported after LT with survival
in the range of 60% to 70% at 5 years.4 However, a major
disadvantage with LT is that many patients faced a long
waiting time for donor organs. This resulted in the devel-
opment of an allocation schema so that the priority for
donor organs is given to the most severely ill patients. In
the United States, this is based on the “model for end-stage
liver disease” (MELD) score, a statistical model predicting
survival in patients with cirrhosis.5,6 Patients with early
HCC accrue MELD exception points based on waitlist
time. Nationally, the median time from HCC exception to
transplant is 77 days, though this varies greatly by United
Network for Organ Sharing region; a recent policy change
delaying the award of exception points will unquestionably
extend this interval.7
Several studies have investigated the effect of locore-
gional therapies, such as radiofrequency ablation (RFA),8
transarterial chemoembolization (TACE),9 sorafenib,10
stereotactic body radiation therapy (SBRT),11 and
yttrium-90 (Y90) radioembolization.12 Choice of the
appropriate type of therapy is based on different param-
eters such as size of the tumor, location, bilirubin level,
institutional expertise, and patient preference.
RFA involves the local application of radiofrequency
thermal energy in which a probe emitting a high-frequencyalternating current is inserted into the tumor to destroy
it.13,14 The best outcomes for RFA have been demonstrated
in patients with a single tumor <4 cm in diameter.15
Several studies have shown that TACE is effective in
terms of achieving tumor necrosis as demonstrated on
explant analysis.16 TACE can be performed by injection
of a chemotherapeutic agent, with or without lipiodol, or
using drug-eluting beads (DEBs) which can be loaded
with cytotoxic drugs such as doxorubicin. DEB-TACE
provides signiﬁcantly better tumor response compared
with conventional TACE, with a similar safety proﬁle.17
Radioembolization is a form of brachytherapy in which
Y90 microspheres are injected via the hepatic artery and
trapped within the microvasculature of the tumor. Beneﬁts
over other forms of local therapy include relatively low
toxicity and the potential to treat patients with signiﬁcant
tumor burden.18 Y90 radioembolization is most commonly
used as a treatment for patients with advanced HCC not
eligible for transplantation. However, there is an increasing
role for Y90 radioembolization in downstaging or as a
bridge therapy for patients awaiting LT.12
SBRT is a technique in which a single or limited
number of high-dose fractions are delivered to a small
precisely deﬁned target, allowing for the treatment of
HCC while limiting damage to the normal liver
parenchyma.19
In our study, we report our center’s experience in using
TACE, SBRT, Y90, and RFA. We evaluate and compare
the treatment effect and outcomes of these therapies
before and after LT.
Methods and Materials
We conducted an institutional review boardeapproved
retrospective review of the transplant surgery database
and identiﬁed all transplanted patients treated at our
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LT between 2006 and 2013. We analyzed radiologic and
pathologic response as well as rate of failure after bridge
therapy. The Kaplan-Meier method was used to calculate
OS and DFS after LT.Study population
In our study, 60 patients received 79 therapies with
SBRT, TACE, RFA, or Y-90 as bridge to LT. Diagnosis
of HCC was based on biopsy sample or American As-
sociation for the Study of Liver Disease imaging
criteria.20 The strategy for managing HCC patients at our
institute is determined at a multidisciplinary tumor board
including transplant surgeons, medical and radiation on-
cologists, interventional radiologists, and pathologists.SBRT technique
All patients were immobilized using a vacuum cushion
device during simulation and treatment. An end-
expiratory shallow breath-hold technique was used in
conjunction with the ExacTrac patient positioning plat-
form (BrainLAB AG, Heimstetten, Germany). The gross
tumor volume was contoured on treatment planning
computed tomography (CT) fused with contrast enhanced
CT or magnetic resonance imaging. No margin was added
for the clinical target volume, but a minimum of 10 mm
was added to the craniocaudal margin, and 7 mm to the
other margins for the planning target volume.
Treatment was prescribed to the 100% isodose line,
with the 80% isodose line covering the planning target
volume, and delivered using conformal arcs or multiple
ﬁxed coplanar beams. A normal liver volume of 1000 mL,
deﬁned as the volume of liver not involved by gross
tumor, was required. The dose to 70% of the normal liver
was not to exceed 27 Gy.Radiologic response and toxicity evaluation
All patients in the study were assessed for radiological
response and toxicity. We assessed ﬁrst radiological
response and acute toxicity either after the initial or
subsequent bridge therapies before transplant. Radiolog-
ical response was assessed using Response Evaluation
and Criteria in Solid Tumors.21 Tumor response was
evaluated by CT or magnetic resonance imaging.
Downstaging was deﬁned as regression of tumor from
stage T3/4 to T1/2 after treatment. Toxicity data were
reviewed from hospital records and laboratory data.
Toxicities during and after treatment were reported using
National Cancer Institute Common Toxicity Criteria,
version 4.0.Pathologic response
We evaluated the effect of treatment on the tumor by
histological assessment of tumor necrosis relative to the
total tumor volume. Pathologic complete response (pCR)
was 100% tumor necrosis and the absence of any viable
tumor; signiﬁcant pathologic response was >50% tumor
necrosis in cross-section; minimal pathologic response
was <50% tumor necrosis in cross-section; and viable
tumor was no tumor necrosis present.
Statistics
Statistical analysis was performed using SPSS
software (version 17.0; SPSS, Chicago, IL). Descriptive
statistics were performed on sociodemographic and
disease-speciﬁc variables. OS and DFS were obtained by
Kaplan-Meier survival analyses (log-rank). A P value of
less than .05 was considered statistically signiﬁcant.
Treatment outcomes and toxicity in different treatment
groups was done using c2 tests or the analysis of variance
test.
Results
Sixty patients received a total of 79 therapies with
SBRT (nZ 24), TACE (nZ 37), RFA (nZ 9), and Y90
(n Z 9) as bridge to transplant. HCC diagnosis was
conﬁrmed by biopsy in 27 patients (45%) and by Amer-
ican Association for the Study of Liver Disease criteria in
33 patients (55%). Median age at diagnosis was 57.5
years (range, 44-70.2) with a male predominance (88%).
Child Pugh class A, B, C, and unknown at diagnosis were
22 (37%), 23 (38%), 6 (10%), and 9 (15%) patients,
respectively. Main causes for cirrhosis were hepatitis C
virus infection (31 patients, 51%), alcohol use (14 pa-
tients, 23%), and nonalcoholic steatohepatitis (8 patients,
13%). All patients had Karnofsky score >60 before
treatment.
Of the 60 subjects, 37 patients (61.7%) presented with
1 lesion. The primary bridge therapy they received was
TACE (nZ 22), SBRT (nZ 9), RFA (nZ 5), and Y90
(nZ 1). Eleven patients received further bridge therapies
either from recurrence after initial response (n Z 6) or
progressive or persistent disease (n Z 5).
Twenty-three patients (38.3%) had 2 or more lesions at
presentation. The primary bridge therapy for this group
was TACE (nZ 10), SBRT (n Z 8), RFA (nZ 1), and
Y90 (n Z 4). Eight patients received further bridge
therapies either from recurrence after initial response (n
Z 2), progressive or persistent disease (n Z 2) or for
continuation (for other lesions) (n Z 4).
Forty-seven patients (78.3%) met Milan criteria at
diagnosis and received bridge therapy to prevent pro-
gression before transplant, whereas 13 patients (21.7%)
Table 1 Patients, tumor characteristics, and toxicity evaluation
No. of treatments No. of lesions
treated
Median diameter
of lesion
Median bilirubin
before treatment
CTP A-B before
treatment (known
patients), %
G3 toxicity after
treatment, %
TACE 37 49 2.6 cm 1 96 11
SBRT 24 36 3 cm 2.8 70 0
RFA 9 10 2.5 cm 1.3 100 22
Y90 9 14 3.4cm 1.8 100 0
RFA, radiofrequency ablation; SBRT, stereotactic body radiation therapy; TACE, transarterial chemoembolization; Y90, yttrium 90.
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required downstaging.
Of the 13 patients outside of the Milan criteria at
diagnosis, 6 received SBRT as primary bridge therapy, 5
received TACE, and 2 received Y90. Ten patients suc-
cessfully underwent downstaging before transplant,
whereas 3 went to transplant based on their MELD score
without downstaging.
Treatment details and toxicity evaluation
Our patients received TACE on 37 occasions (33
conventional TACE and 4 DEBs). The most commonly
used chemotherapy agents were cisplatin (n Z 22) and
doxorubicin (n Z 9). Four treatments were combined
with cryotherapy. The most common postprocedure
toxicity was postembolization syndrome, consisting of
fatigue, mild nausea, low-grade fever, and abdominal
pain. Four patients (11%) developed G3 toxicity post-
treatment adverse reactions included: acute renal impair-
ment (n Z 2), high fever and severe pain (n Z 1), and
bleeding and thrombocytopenia (nZ 1). Grade 4 toxicity
was not observed.
SBRT was administered on 24 occasions. Median dose
of radiation was 50 Gy (range, 45-60), median number of
fractions was 5. All patients tolerated treatment well. The
most common side effect was grade 1-2 fatigue, (nZ 6),
and no grade 3 or 4 toxicity was seen.
Seven patients received Y90 therapy on nine occa-
sions. The average dose of radiation was 109 Gy. Grade
1-2 fatigue was observed after three treatments in 3 pa-
tients and elevated liver enzymes after 1 treatment. No
grade 3 or 4 toxicities were observed posttreatment.
Of the 9 RFA treatments, 2 grade 3 toxicities were
observed: pneumothorax and severe pain. There was a
signiﬁcant association between type of bridge therapy
received and occurrence of grade 3-4 toxicity (PZ .046)
(Table 1).
Radiological response after bridge therapies
Evaluation of response was based on the ﬁrst CT/
magnetic resonance imaging scan done after all bridge
therapy received. First radiological assessment was doneat a median of 2.4 months after 77 bridge therapies.
Complete response (CR) was reported after 16 treatments
(20.8%), partial response (PR) after 34 treatments (44%),
stable disease after 23 treatments (29.8%), and progres-
sive disease was reported after only 4 treatments (5.1%).
The number of patients who achieved a signiﬁcant
response (CR or PR) was 61% for TACE (22/36), 65%
for SBRT (15/23), 67% for RFA (6/9), and 67% for Y90
(6/9) (Table 2). There was no signiﬁcant correlation be-
tween type of bridge therapy and the radiological
response achieved. Recurrence after initial response was
observed in 8 of 60 patients after primary bridge therapy
(13.3%), with 4 after TACE, 2 after RFA, and 2 after
Y90. Local control rate after bridge therapy was 80.6%
for TACE, 91.4% for SBRT, 77.8% for Y90, and 77.8%
for RFA.
Liver transplantation and pathologic response
Our patients received a transplant after a median
waiting time on the transplant list of 7.4 months after
bridge therapy; 5.7 months for SBRT, 10 months for
TACE, 7.5 months for RFA, 9.1 months for RFA, and 7.4
months for multiple therapies. At the time of surgery, 57
patients (95%) met Milan criteria, whereas 3 patients (5%)
did not. Ten of 13 patients (77%) who were outside Milan
at diagnosis were successfully downstaged.
Histopathological analysis of the explanted livers
showed 100% tumor necrosis in 40% of patients, 50% to
99% necrosis in 35%, <50% necrosis in 16%, and no
necrosis in 9%. All patients who had complete necrosis
originally met the Milan criteria before transplantation.
Mean pathological necrosis for the whole group was 68%
(95% conﬁdence interval [CI], 58-77); 56% for patients
who received SBRT only (95% CI, 35-77), 68% for
TACE only (95% CI, 54-82), 70% for RFA only (95% CI,
14-125), 94% for Y90 only (95% CI, 73-113), and 73%
for multiple therapies (95% CI, 45-102), (P Z .55)
(Table 3).
Follow-up and survival analysis
The median follow-up was 41 months (7.3-77.9) after
transplantation. Seven patients recurred after transplantation
Table 2 Radiological response after bridge therapy
SBRT (N Z 23) TACE (n Z 36) RFA (n Z 9) Y90 (n Z 9)
CR (n Z 16) 2 (8.6%) 9 (25%) 2 (22.2%) 3 (33.3%)
PR (n Z 34) 13 (56.5%) 13 (36.1%) 4 (44.4%) 3 (33.3%)
SD (n Z 23) 8 (34.7%) 12 (33.3%) 3 (33.3%) 2 (22.2%)
PD (n Z 4) 1 (4.3%) 2 (5.5%) 0 (0%) 1 (11.1%)
Total 23 (100%) 36 (100%) 9 (100%) 9 (100%)
CR, complete response; PD, progressive disease; PR, particle response; RFA, radiofrequency ablation; SBRT, stereotactic body radiation therapy; SD,
stable disease; TACE, transarterial chemoembolization; Y90, yttrium 90.
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extrahepatic distant metastasis, and 1 had both local and
distant recurrence. Five-year DFS was 86%. The total
number of deathswas 8 (13.3%) and 5-year OS 79% (Fig 1).
Patients who had a pCR (vs no pCR) in the explanted liver
were less likely to experience disease recurrence (32% pCR
in patients with no recurrence vs 14% pCR in patients with
recurrence) after transplant (PZ .14).
None of the patients who received Y90, RFA, or
multiple therapies recurred or died during the time of the
study. One of the 17 patients who received SBRT only
recurred after transplantation, and 4 of them died. Five of
the 24 patients who received TACE only recurred after
transplantation, and 4 had died by the end of study. Five-
year DFS for SBRT was 91% vs 73% for TACE. Five-
year OS for SBRT and TACE was 73% and 72%,
respectively.Discussion
LT is a curative treatment for early-stage HCC.
However, many patients face the problem of organ
availability and may drop off the waiting list because of
tumor progression. Different locoregional therapies
have been used as bridge to transplant. The choice of
the optimal modality is usually undertaken through
multidisciplinary tumor boards based on numerous
parameters.Table 3 Pathological response
Bridge therapy received Pathological response
100% necrosis
(n Z 23)
50%-99%
necrosis
(n Z 20)
No. % No. %
SBRT 4 28.5 6 42.8
TACE 10 41.7 8 33.3
RFA 3 60 1 20
Y90 3 75 1 25
Multiple therapies 3 30 4 40
RFA, radiofrequency ablation; SBRT, stereotactic body radiation therapy; TWe analyzed and compared the ﬁrst radiological
response, acute toxicity, pathological response, and long-
term outcomes after LT among 4 of the most commonly
used bridging therapies. There are limited studies that
compare the outcomes of these modalities, especially for
SBRT and Y90, which are relatively new compared with
TACE and RFA (Table 4).
In our study, the choice of the bridging therapy was
affected by several patient and tumor characteristics. Pa-
tients with high pretreatment bilirubin level and Child C
status received SBRT, whereas RFA was directed at
smaller lesions (mean diameter, 2.5 cm). The ideal in-
dications for RFA include tumor size <3 cm, <3 nodules,
and no major vascular or biliary structure near the target
lesions.14 Y90 has the advantage of covering areas with
high tumor burden and is widely used in the nontransplant
setting.22 In this study, the median diameter for Y90 was
the highest among the 4 therapies (3.4 cm).
Major toxicities which required hospitalization were
reported only after TACE (4/37) (all with the conven-
tional method) and RFA (2/9). None of our patients
who received SBRT or Y90 developed major toxicities.
Mazzafero et al14 reported the results of 40 transplant
candidates who received a single session of RFA before
LT, of whom 4 developed major toxicities. A Chinese
study23 of 20 patients showed no grade 3 or 4 toxicity
after SBRT, although this study was conducted in pa-
tients whose cases were inoperable or who had refused
LT/surgery.<50%
necrosis
(n Z 9)
No necrosis
(n Z 5)
Total (n Z 57)
No. % No. %
2 14.2 2 14.2 14 (100%)
5 20.8 1 4.1 24 (100%)
0 0.0 1 20.0 5 (100%)
0 0.0 0 0.0 4 (100%)
2 20 1 10 10 (100%)
ACE, transarterial chemoembolization; Y90, yttrium 90.
Figure 1 Overall survival for the whole group at 5 years: 79%.
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rable among the 4 modalities (ranges between 61% and 67%)
when taking into consideration the differences in mean tumor
diameters. As for pathologic response, we report promising
results in patients who received Y90 or RFA only before
transplant. Tohme et al12 reported complete tumor necrosis in
25% of 20 explanted livers who received Y90 as bridge to
transplant. Also among 16 patients who had radiological
follow up, 56% of them had signiﬁcant response (CR, PR).
Lewandowski et al24 demonstrated that transarterial
Y90 radioembolization was associated with greater partial
response rates compared with chemoembolization in
downstaging HCC from United Network for Organ
Sharing stage T3 to T2. Some studies which studied RFA
as bridge to transplant have reported complete tumor
necrosis at histopathological analysis after LT in 47% to
75% of cases.25,26 These results were consistent with our
ﬁndings.Table 4 Summary of most important studies of bridge therapies f
Reference Treatment Tumor stage Tran
patie
Present series SBRT, TACE,
Y90, RFA
47 inside Milan
13 outside
60 (1
Mazzafero et al, 200422 RFA 40 inside
10 outside
50 (1
Katz et al, 201211 SBRT 15 inside
3 outside
11 w
(6
Tohme et al, 201312 Y90 14 inside
6 outside
20 (1
Maddala et al, 200429 TACE 47 inside
7 outside
46 (8
Yao et al, 200330 TACE, RFA,
PEI, resection
70 inside 38 (5
HCC, hepatocellular carcinoma; LT, liver transplantation; NA, not available
SBRT, stereotactic body radiation therapy; TACE, transarterial chemoembolOur experience with SBRT showed radiological CR/
PR of 65% (15/23). Similar results were reported from
Andolino et al27 who demonstrated 75% CR/PR rate (18/
24), with median tumor size of 3 cm. SBRT is being
recognized as an effective therapy for HCC either alone or
in combination with other modalities, especially in large
tumors not suitable for other types of locoregional ther-
apies. Although its clinical experience is still limited,
SBRT is a promising option for bridging prior to trans-
plant (Table 4).
TACE was delivered in our study either by conven-
tional means (33 treatments) or DEBs (4 treatments).
Radiological CR-PR was 61%. An important point to
mention is that the CR-PR rate was 100% after the 4
treatments of DEBs, and no grade 3 toxicity was reported.
The PRECISION trial which compared conventional
TACE vs DEB showed that the [CR þ PR þ stable dis-
ease] rate was superior for DEBs (63.4% vs 51.9%), inor HCC before liver transplantation
splanted
nts
Tumor
progression
Waiting Time
(months)
Survival after LT
00%) 4 7.4 79% at 5 years
00%) 0 (0%) 9.5 83% at 3 years
ith 1 resection
6.6%)
3 6.3 NA
00%) 0 3.5 79% at 5 years
5%) 6 (11%) 7.0 74% at 5 years
4%) 18 (26%) 6.1 NA
; PEI, percutaneous ethanol injection; RFA, radiofrequency ablation;
ization; Y90, yttrium 90.
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setting.28 Interestingly, in this study, only 1 of the patients
who achieved radiological CR and 1 patient who had
complete tumor necrosis after transplant developed
recurrence after surgery, which shows that response after
bridging therapy can be used as a prognostic tool for
recurrence after transplantation.
In conclusion, the 4 bridge treatment modalities used
on the 60 patients in our study were effective as
demonstrated by good pathological response and DFS
after LT. Radiological response after bridge therapy was
comparable among the 4 therapies, though SBRT and
Y90 were superior to TACE and RFA in terms of acute
toxicity. Choice of the optimal modality depends on
various factors such as tumor size, pretreatment bilirubin
level, Child-Pugh score, and patient preference. We
recommend that this decision be made at a multidisci-
plinary tumor board including medical and radiation on-
cologists, transplant surgeons, transplant hepatologists,
and interventional radiologists.
Although the results of this study were decidedly
encouraging, there are some limitations that need to be
considered when reviewing this study. One of the limi-
tations may be the relatively modest sample size that was
60 patients and that only 4 modalities of treatment were
investigated. This may limit withdrawing comparative
conclusions about treatment and toxicity. Larger samples
are needed to further validate our ﬁndings. Another lim-
itation for this study might be the fact that several patients
received more than one treatment which might further
weaken the decisive results for the effect of each
treatment.Acknowledgments
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